Healthy Longevity ScienceExplore the questions behind healthy longevity. Understand the evidence, its possibilities and its limits.
6 articles
Medicines and longevityRapamycin (sirolimus) has mixed human evidence for healthy aging. PEARL found no improvement in its main body-fat measure over 48 weeks, and RAPA-EX-01 found no added functional benefit alongside exercise. Everolimus improved selected vaccine responses, while a larger RTB101 trial missed its respiratory-illness endpoint. Healthy Longevity Clinic weighs these results by function, infection prevention and tolerability.
Medicines and longevityMetformin helps control type 2 diabetes and reduced new diabetes cases by 31% relative to placebo in the Diabetes Prevention Program. That is a meaningful healthspan benefit for people at high risk. This review distinguishes established prevention from newer frailty findings, exercise trade-offs and the proposed TAME trial, which aims to test broader prevention of age-related disease.
Medicines and longevitySemaglutide has shown benefits beyond weight loss. In SELECT, serious cardiovascular events occurred in 6.5% of treated adults versus 8.0% with placebo; participants had cardiovascular disease and overweight or obesity, without diabetes. Kidney and symptom benefits in other defined groups add to the healthspan picture. Healthy Longevity Clinic examines who benefited, how much, and which risks affect the decision.
Medicines and longevityRetatrutide has produced substantial weight loss in clinical trials. In one phase 3 study, Lilly reported an average reduction of 28.7% versus 2.1% with placebo over 68 weeks in an analysis assuming continued treatment. Published research also shows improved glucose control in type 2 diabetes. These benefits warrant attention, but cardiovascular protection, long-term safety and an approval date remain unsettled.
Medicines and longevityDasatinib–quercetin, fisetin and the experimental drugs UBX0101 and UBX1325 test whether removing senescent cells can improve bone, lung, joint or eye health. Results are mixed: several trials missed their main goals, while narrower biological and visual signals warrant follow-up. Healthy Longevity Clinic compares the prospects for fewer fractures, better mobility and preserved vision, together with treatment risks.
Medicines and longevityMetformin, semaglutide and dapagliflozin reduce diabetes or serious heart and kidney events in defined patient groups. Evidence for rapamycin (sirolimus), the senolytic combination dasatinib–quercetin and the NAD precursor nicotinamide riboside (NR) remains early or mixed. This September 2026 overview also compares testosterone and menopausal hormone therapy. Healthy Longevity Clinic assesses their healthspan value through disease prevention, physical function and symptom relief.